title: Progress towards development of a cholera subunit vaccine.
abstract: Cholera, an enteric disease that can reach pandemic proportions, remains a world-wide problem that is positioned to increase in incidence as changes in global climate or armed conflict spawn the conditions that enhance transmission to humans and, thus, precipitate epidemic cholera. An effective subunit cholera vaccine that can provide protective immunity with one parenteral immunization would be a major advantage over the existing oral vaccines that can require two doses for optimal protection. The existing vaccines are clearly effective in some settings, but are less so in others, especially with respect to specific groups such as young (2-5 years) children. In our efforts to develop a cholera subunit vaccine, we focused on two Vibrio cholerae antigens, LPS (lipopolysaccharide) and TCP (toxin co-regulated pilus), that are known to induce protective antibodies in animal models and, in the case of anti-LPS antibodies, to be associated with clinical protection of V. cholerae exposed or vaccinated individuals. This review discusses the current cholera vaccines and compares the advantages of a cholera subunit vaccine to that of the whole cell vaccines. We discuss the possible subunit antigens and prospective targeted use of a subunit cholera vaccine.
authors.affiliation: Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH 03756, USA.
authors.forename: Ronald K
authors.initials: RK
authors.lastname: Taylor
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Kirn
authors.forename: Niranjan
authors.initials: N
authors.lastname: Bose
authors.forename: Emily
authors.initials: E
authors.lastname: Stonehouse
authors.forename: Shital A
authors.initials: SA
authors.lastname: Tripathi
authors.forename: Pavol
authors.initials: P
authors.lastname: Kovác
authors.forename: William F
authors.initials: WF
authors.lastname: Wade
mesh_terms: D000818:Animals; D002771:Cholera / Q000517:prevention & control* / Q000635:transmission; D022121:Cholera Vaccines / Q000737:chemistry* / Q000627:therapeutic use; D006801:Humans; D013678:Technology, Pharmaceutical / Q000639:trends; D014613:Vaccines, Attenuated / Q000737:chemistry / Q000627:therapeutic use; D015164:Vaccines, Inactivated / Q000737:chemistry / Q000627:therapeutic use; D022223:Vaccines, Subunit / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D022121:Cholera Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D022223:Vaccines, Subunit